Exodus Point Capital Management, LP Fate Therapeutics Inc Transaction History

Exodus Point Capital Management, LP

  • $16.4 Billion
  • Q3 2024

A detailed history of Exodus Point Capital Management, LP transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 80,670 shares of FATE stock, worth $118,584. This represents 0.0% of its overall portfolio holdings.

Number of Shares
80,670
Holding current value
$118,584
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
BUY
$3.12 - $5.57 $251,690 - $449,331
80,670 New
80,670 $282,000
Q3 2023

Nov 09, 2023
SELL
$2.02 - $5.04 $10,544 - $26,308
-5,220 Reduced 21.52%
19,031 $40,000
Q2 2023

Aug 10, 2023
SELL
$4.76 - $6.59 $347,403 - $480,964
-72,984 Reduced 75.06%
24,251 $115,000
Q1 2023

May 11, 2023
SELL
$4.24 - $11.12 $629,737 - $1.65 Million
-148,523 Reduced 60.43%
97,235 $554,000
Q4 2022

Feb 13, 2023
BUY
$9.86 - $23.83 $2.17 Million - $5.25 Million
220,284 Added 864.74%
245,758 $2.48 Million
Q3 2022

Nov 10, 2022
BUY
$21.04 - $36.06 $535,972 - $918,592
25,474 New
25,474 $571,000
Q4 2021

Feb 11, 2022
SELL
$47.84 - $64.34 $654,738 - $880,557
-13,686 Closed
0 $0
Q3 2021

Nov 15, 2021
BUY
$59.27 - $95.73 $217,283 - $350,946
3,666 Added 36.59%
13,686 $811,000
Q2 2021

Aug 16, 2021
BUY
$67.25 - $92.52 $673,845 - $927,050
10,020 New
10,020 $870,000
Q1 2021

May 17, 2021
SELL
$72.16 - $117.4 $985,056 - $1.6 Million
-13,651 Closed
0 $0
Q4 2020

Feb 16, 2021
BUY
$38.09 - $100.95 $519,966 - $1.38 Million
13,651 New
13,651 $1.24 Million
Q2 2020

Aug 14, 2020
SELL
$20.21 - $35.23 $242,802 - $423,253
-12,014 Closed
0 $0
Q1 2020

May 15, 2020
BUY
$17.28 - $31.88 $207,601 - $383,006
12,014 New
12,014 $267,000

Others Institutions Holding FATE

# of Institutions
175
Shares Held
115M
Call Options Held
53.7K
Put Options Held
9K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $143M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email